The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies
Open accessAbstract
No consensus on the indications for surgical resection of colorectal liver metastases exists. This systematic review has been undertaken to assess the published evidence for its efficacy and safety and to identify prognostic factors. Studies were identified by computerised and hand searches of the literature, scanning references and contacting investigators. The outcome measures were overall survival, disease-free survival, postoperative morbidity and mortality, quality of life and cost effectiveness, and a qualitative summary of the trends across all studies was produced. Only 30 of 529 independent studies met all the eligibility criteria for the review, and data on 30-day mortality and morbidity only were included from a further nine studies. The best available evidence came from prospective case series, but only two studies reported outcomes for all patients undergoing surgery. The remainder reported outcomes for selected groups of patients: those undergoing hepatic resection or those undergoing curative resection. Postoperative mortality rates were generally low (median 2.8%). The majority of studies described only serious postoperative morbidity, the most common being bile leak and associated perihepatic abscess. Approximately 30% of patients remained alive 5 years after resection and around two-thirds of these are disease free. The quality of the majority of published papers was poor and ascertaining the benefits of surgical resection of colorectal hepatic metastases is difficult in the absence of randomised trials. However, it is clear that there is group of patients with liver metastases who may become long-term disease-free survivors following hepatic resection. Such survival is rare in apparently comparable patients who do not have surgical treatment. Further work is needed to more accurately define this group of patients and to determine whether the addition of adjuvant treatments results in improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“When monoclonal biological agents are added to cytotoxic chemotherapy, the prospect of median survival now extends beyond 2 years, and 20% of patients will still be alive 4 years after detection of unresectable liver disease (Cunningham et al, 2004; Hurwitz et al, 2004; Saltz et al, 2004).”
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“Chemotherapy used alone is palliative but may prolong the survival of patients with unresectable disease (de Gramont et al, 2000; Douillard et al, 2000; Saltz et al, 2000; Simmonds, 2000).”
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Cited by
Rees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., & John, T. G. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815aa2c2 · Cited by 1,026
Self-citationFolprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70330-4 · Cited by 963
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Taylor, A., Primrose, Langeberg, W., Kelsh, Mowat, F., Alexander, D., Choti, M., Poston, G., & Kanas, G. (2012) · Clinical Epidemiology · doi:10.2147/clep.s34285 · Cited by 657
Self-citationAdam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., Sobrero, A., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.006 · Cited by 607
Self-citationPfannschmidt, J., Dienemann, H., & Hoffmann, H. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.02.093 · Cited by 557
Stereotactic body radiotherapy for oligometastases
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70510-7 · Cited by 524
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Halazun, K. J., Aldoori, A., Malik, H. Z., Al-Mukhtar, A., Prasad, K. R., Toogood, G. J., & Lodge, J. P. A. (2008) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2007.02.014 · Cited by 444
Van Den Broek, M. A. J., Olde Damink, S. W. M., Dejong, C. H. C., Lang, H., Malagó, M., Jalan, R., & Saner, F. H. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01777.x · Cited by 438
de Haas, R. J., Wicherts, D. A., Flores, E., Azoulay, D., Castaing, D., & Adam, R. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31818a07f1 · Cited by 427
Guidelines for resection of colorectal cancer liver metastases
Garden, O. J. (2006) · Gut · doi:10.1136/gut.2006.098053 · Cited by 417
Self-citationPeng, P. D., van Vledder, M. G., Tsai, S., de Jong, M. C., Makary, M., Ng, J., Edil, B. H., Wolfgang, C. L., Schulick, R. D., Choti, M. A., et al. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00301.x · Cited by 413
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 410
How Much Remnant Is Enough in Liver Resection?
Guglielmi, A., Ruzzenente, A., Conci, S., Valdegamberi, A., & Iacono, C. (2012) · Digestive Surgery · doi:10.1159/000335713 · Cited by 365
Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases
Wicherts, D. A., Miller, R., de Haas, R. J., Bitsakou, G., Vibert, E., Veilhan, L.-A., Azoulay, D., Bismuth, H., Castaing, D., & Adam, R. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e3181907fd9 · Cited by 332
Colorectal cancer: Metastases to a single organ
Vatandoust, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11767 · Cited by 308
Castaing, D., Vibert, E., Ricca, L., Azoulay, D., Adam, R., & Gayet, B. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181bcaf63 · Cited by 277
Metadata
- Authors
- Simmonds, P. C., Primrose, J. N., Colquitt, J. L., Garden, O. J., Poston, G. J., & Rees, M.
- Venue
- British Journal of Cancer
- Published
- 2006-03-14
- Volume
- 94
- Issue
- 7
- Pages
- 982-999
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2146182990
- Cited by
- 858
- References
- 53
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.